Compare
Skye Bioscience, Inc. vs Biofrontera Inc. vs Neuphoria Therapeutics Inc. vs TuHURA Biosciences, Inc.
| Latest fiscal year | Skye Bioscience, Inc. SKYE | Biofrontera Inc. BFRI | Neuphoria Therapeutics Inc. NEUP | TuHURA Biosciences, Inc. HURA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | $41.70M | $1.17M | $0 |
| Revenue growth (YoY) | n/a | +11.7% | -92.5% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -27.2% | n/m | n/a |
| Net margin | n/a | -25.3% | n/m | n/a |
| Net income | -$55.92M | -$10.54M | -$13.45M | -$30.05M |
| EPS (Diluted) | -$1.41 | -$1.04 | -$3.06 | -$0.63 |
| Operating cash flow | -$43.06M | -$13.36M | -$12.35M | -$27.63M |
| Free cash flow | -$43.07M | -$13.36M | n/a | -$27.71M |
| Cash & equivalents | $5.88M | $6.39M | $19.87M | $3.62M |
| Total assets | $28.31M | $28.56M | $28.71M | $27.35M |
| Total liabilities | $8.29M | $18.08M | $4.11M | $6.42M |
| Shareholders' equity | $20.02M | $10.48M | $24.60M | $20.93M |
| Return on year-end equity | -279.3% | -100.5% | -54.7% | -143.6% |
| Shares outstanding | 33.38M | 11.65M | 5.41M | 59.34M |
Revenue, most recent five fiscal years
| Fiscal year | Skye Bioscience, Inc. | Biofrontera Inc. | Neuphoria Therapeutics Inc. | TuHURA Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | $41.70M Ended 2025-12-31 | $1.17M Ended 2026-06-30 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | $37.32M Ended 2024-12-31 | $15.65M Ended 2025-06-30 | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $34.07M Ended 2023-12-31 | n/a | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $28.67M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $24.10M Ended 2021-12-31 | n/a | n/a |